Genfit S.A. (GNFT.PA)
EUR 3.5
(2.04%)
EUR 3.5
(2.04%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 28.56 Million EUR | 41.45% |
| 2022 | 20.19 Million EUR | -74.78% |
| 2021 | 80.06 Million EUR | 10366.54% |
| 2020 | 765 Thousand EUR | -97.52% |
| 2019 | 30.83 Million EUR | 44594.2% |
| 2018 | 69 Thousand EUR | -41.53% |
| 2017 | 118 Thousand EUR | -58.45% |
| 2016 | 284 Thousand EUR | -46.11% |
| 2015 | 527 Thousand EUR | -67.36% |
| 2014 | 1.61 Million EUR | -15.0% |
| 2013 | 1.89 Million EUR | 13.57% |
| 2012 | 1.67 Million EUR | -29.17% |
| 2011 | 2.36 Million EUR | -37.17% |
| 2010 | 3.75 Million EUR | -35.35% |
| 2009 | 5.81 Million EUR | -33.66% |
| 2008 | 8.76 Million EUR | -7.56% |
| 2007 | 9.47 Million EUR | -5.72% |
| 2006 | 10.05 Million EUR | -21.31% |
| 2005 | 12.77 Million EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 61.1 Million EUR | 0.0% |
| 2023 Q3 | 2.81 Million EUR | -75.46% |
| 2023 FY | 28.56 Million EUR | 41.45% |
| 2023 Q2 | 11.48 Million EUR | 0.0% |
| 2023 Q4 | 17.08 Million EUR | 506.21% |
| 2022 Q2 | 8.79 Million EUR | 0.0% |
| 2022 Q3 | 5.31 Million EUR | -39.59% |
| 2022 FY | 20.19 Million EUR | -74.78% |
| 2022 Q4 | 6.09 Million EUR | 14.78% |
| 2021 Q2 | 11 Thousand EUR | 0.0% |
| 2021 Q4 | 80.05 Million EUR | 0.0% |
| 2021 FY | 80.06 Million EUR | 10366.54% |
| 2020 Q4 | 643 Thousand EUR | 0.0% |
| 2020 FY | 765 Thousand EUR | -97.52% |
| 2020 Q2 | 122 Thousand EUR | 0.0% |
| 2019 Q4 | 30.83 Million EUR | 0.0% |
| 2019 FY | 30.83 Million EUR | 44594.2% |
| 2019 Q2 | 1000.00 EUR | -99.99% |
| 2019 Q1 | 7.7 Million EUR | 214.94% |
| 2018 FY | 69 Thousand EUR | -41.53% |
| 2018 Q4 | 2.44 Million EUR | 0.0% |
| 2018 Q2 | 5.04 Million EUR | 174.09% |
| 2018 Q1 | 1.84 Million EUR | -17.7% |
| 2017 Q4 | 2.23 Million EUR | 0.0% |
| 2017 FY | 118 Thousand EUR | -58.45% |
| 2017 Q1 | 29.5 Thousand EUR | -99.04% |
| 2017 Q2 | 4.61 Million EUR | 15557.63% |
| 2016 FY | 284 Thousand EUR | -46.11% |
| 2016 Q2 | 3.57 Million EUR | 4939.44% |
| 2016 Q1 | 71 Thousand EUR | -96.24% |
| 2016 Q4 | 3.08 Million EUR | 0.0% |
| 2015 FY | 527 Thousand EUR | -67.36% |
| 2015 Q3 | 131.75 Thousand EUR | -94.41% |
| 2015 Q2 | 2.35 Million EUR | 1689.75% |
| 2015 Q1 | 131.75 Thousand EUR | -95.75% |
| 2015 Q4 | 1.88 Million EUR | 1331.5% |
| 2014 FY | 1.61 Million EUR | -15.0% |
| 2014 Q1 | 403.6 Thousand EUR | -86.83% |
| 2014 Q3 | 403.6 Thousand EUR | -88.72% |
| 2014 Q2 | 3.57 Million EUR | 786.77% |
| 2014 Q4 | 3.1 Million EUR | 668.83% |
| 2013 Q3 | 474.82 Thousand EUR | -82.74% |
| 2013 FY | 1.89 Million EUR | 13.57% |
| 2013 Q4 | 3.06 Million EUR | 545.37% |
| 2013 Q2 | 2.75 Million EUR | 479.41% |
| 2013 Q1 | 474.82 Thousand EUR | 0.0% |
| 2012 Q1 | 418.07 Thousand EUR | 0.0% |
| 2012 Q4 | 474.82 Thousand EUR | 13.57% |
| 2012 FY | 1.67 Million EUR | -29.17% |
| 2012 Q2 | 418.07 Thousand EUR | 0.0% |
| 2012 Q3 | 418.07 Thousand EUR | 0.0% |
| 2011 Q3 | 590.22 Thousand EUR | 0.0% |
| 2011 Q1 | 590.22 Thousand EUR | 0.0% |
| 2011 Q2 | 590.22 Thousand EUR | 0.0% |
| 2011 Q4 | 418.07 Thousand EUR | -29.17% |
| 2011 FY | 2.36 Million EUR | -37.17% |
| 2010 Q1 | 939.37 Thousand EUR | 0.0% |
| 2010 Q2 | 939.37 Thousand EUR | 0.0% |
| 2010 Q3 | 939.37 Thousand EUR | 0.0% |
| 2010 Q4 | 590.22 Thousand EUR | -37.17% |
| 2010 FY | 3.75 Million EUR | -35.35% |
| 2009 FY | 5.81 Million EUR | -33.66% |
| 2009 Q4 | 939.37 Thousand EUR | -35.35% |
| 2009 Q3 | 1.45 Million EUR | 0.0% |
| 2009 Q2 | 1.45 Million EUR | 0.0% |
| 2009 Q1 | 1.45 Million EUR | 0.0% |
| 2008 Q2 | 2.19 Million EUR | 0.0% |
| 2008 Q4 | 1.45 Million EUR | -33.66% |
| 2008 Q3 | 2.19 Million EUR | 0.0% |
| 2008 Q1 | 2.19 Million EUR | 0.0% |
| 2008 FY | 8.76 Million EUR | -7.56% |
| 2007 Q2 | 2.36 Million EUR | 0.0% |
| 2007 Q3 | 2.36 Million EUR | 0.0% |
| 2007 Q4 | 2.19 Million EUR | -7.56% |
| 2007 FY | 9.47 Million EUR | -5.72% |
| 2007 Q1 | 2.36 Million EUR | 0.0% |
| 2006 Q2 | 2.51 Million EUR | 0.0% |
| 2006 Q4 | 2.36 Million EUR | -5.72% |
| 2006 FY | 10.05 Million EUR | -21.31% |
| 2006 Q1 | 2.51 Million EUR | 0.0% |
| 2006 Q3 | 2.51 Million EUR | 0.0% |
| 2005 Q3 | 3.19 Million EUR | 0.0% |
| 2005 FY | 12.77 Million EUR | 0.0% |
| 2005 Q2 | 3.19 Million EUR | 0.0% |
| 2005 Q1 | 3.19 Million EUR | 0.0% |
| 2005 Q4 | 2.51 Million EUR | -21.31% |
| 2004 Q4 | 3.19 Million EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.64 Million EUR | -515.625% |
| ABIVAX Société Anonyme | 4.62 Million EUR | -518.156% |
| Adocia SA | 2.15 Million EUR | -1228.605% |
| Aelis Farma SA | 9.05 Million EUR | -215.496% |
| Biophytis S.A. | - EUR | -Infinity% |
| Advicenne S.A. | 3.15 Million EUR | -806.538% |
| genOway Société anonyme | 20.04 Million EUR | -42.495% |
| IntegraGen SA | 12.53 Million EUR | -127.838% |
| Medesis Pharma S.A. | 300.03 Thousand EUR | -9420.588% |
| Neovacs S.A. | 533.41 Thousand EUR | -5255.148% |
| NFL Biosciences SA | - EUR | -Infinity% |
| Plant Advanced Technologies SA | 1.68 Million EUR | -1598.766% |
| Quantum Genomics Société Anonyme | 19.79 Thousand EUR | -144196.828% |
| Sensorion SA | 4.74 Million EUR | -502.248% |
| Theranexus Société Anonyme | 296.33 Thousand EUR | -9539.558% |
| TME Pharma N.V. | 17 Thousand EUR | -167929.412% |
| Valbiotis SA | 4.73 Million EUR | -503.528% |
| TheraVet SA | 1.07 Million EUR | -2549.679% |
| Valerio Therapeutics Société anonyme | 1.8 Million EUR | -1486.944% |
| argenx SE | 1.13 Billion EUR | 97.482% |
| BioSenic S.A. | 543 Thousand EUR | -5160.589% |
| Celyad Oncology SA | 102 Thousand EUR | -27904.902% |
| DBV Technologies S.A. | - EUR | -Infinity% |
| Galapagos NV | 239.72 Million EUR | 88.084% |
| GeNeuro SA | - EUR | -Infinity% |
| Hyloris Pharmaceuticals SA | 2.08 Million EUR | -1268.711% |
| Innate Pharma S.A. | 51.9 Million EUR | 44.963% |
| Inventiva S.A. | 17.47 Million EUR | -63.443% |
| MaaT Pharma SA | 2.22 Million EUR | -1182.092% |
| MedinCell S.A. | 9.16 Million EUR | -211.845% |
| Nanobiotix S.A. | 30.05 Million EUR | 4.967% |
| Onward Medical N.V. | 532 Thousand EUR | -5269.361% |
| Oryzon Genomics S.A. | 14.19 Million EUR | -101.281% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | -1182.667% |
| Oxurion NV | 263 Thousand EUR | -10761.217% |
| Pharming Group N.V. | 245.31 Million EUR | 88.356% |
| Poxel S.A. | 1.98 Million EUR | -1341.949% |
| GenSight Biologics S.A. | 1.26 Million EUR | -2154.538% |
| Transgene SA | 1.18 Million EUR | -2312.584% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 5.25 Billion EUR | 99.456% |
| Valneva SE | 153.71 Million EUR | 81.417% |
| Vivoryon Therapeutics N.V. | -3.62 Million EUR | 889.088% |